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Promoting self-management and monitoring physical activity are important strategies in 
chronic heart disease (CHD) management. The six-minute walk test (6MWT) is a 
commonly used sub-maximal exercise test for measuring physical functional capacity.  
 
Aim 
The aim of this paper is to provide a comprehensive review and critique of the current 
literature on 6MWT in relation to monitoring and measuring physical functional 
capacity as well as exploring the potential  of the protocol to be adopted as a self-
administered exercise test.  
 
Method 
The Medline, CINAHL, Science Direct and the World Wide Web using the search 
engine Google, were searched using the key words "six-minute walk test"; "6MWT"; 
"exercise test”,   “heart disease"; " physical functional capacity", “chronic heart failure” 
from 1985-2008. Articles administration, reliability and validity of the 6MWT were 
sourced. 
 
Findings of the integrative literature review 
The 6MWT is a simple, safe and inexpensive sub-maximal exercise test. The 6MWT 
distance is strongly associated with functional capacity, and it is a useful prognostic tool. 
To date, the capacity for self-administration of the 6MWT has not been investigated.  
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Conclusions 
Adapting the 6MWT as a patient-reported outcome measure may enhance the capacity, 
not only for clinicians to monitor functional status, but also promote self-management 
by enabling individuals to monitor changes in their functional capacity. 
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Coronary heart disease and physical activity 
 
Coronary heart disease (CHD) is the leading cause of death worldwide and has reached 
epidemic proportions.(1, 2) The prognosis for people with CHD is closely related to 
their physical functional capacity.(3) In CHD, physical functional capacity is influenced 
by pathophysiological changes and symptom burden.(4) It is known that moderate 
physical exercise (150 minutes per week), not only reduces the risk of CHD by 
approximately 30%,(2) but can also reduce symptoms associated with the disease and 
decrease mortality. In spite of this fact, up to 60% of the population globally are not 
performing sufficient levels of physical exercise.(2) As a consequence, promoting 
physical activity and monitoring physical functional capacity has become an important 
strategy in preventing and managing CHD. There are well-documented barriers in 
engaging in physical activity and these factors can be intrinsic, for example low self-
efficacy, and extrinsic such as the inaccessibility of resources. The maximal exercise 
test is a test with progressively increasing work rates using exercise equipment, such as a 
bike or a treadmill, until volitional fatigue occurs determining maximal oxygen 
consumption.(5) The purpose of a maximal exercise test is to assess the peak rate of 
oxygen consumption, anaerobic threshold and cardiopulmonary function. However, its 
cost, safety issues, risk of adverse outcomes and the fact that these tests need to be 
performed by an experienced health care professional often limit the use of maximal 
exercise testing. Compared to the maximal exercise test, submaximal exercise testing 
has a lower level of intensity and does not require the use of technology. When 
assessing the application of maximal or submaximal exercise testing, there is a need to 
appraise the strengths and limitations of each of these approaches. 
The six-minute walk test (6MWT) has been devised as a practical sub-maximal walk 
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test, measuring the distance that patients walked on a flat hard surface over a period of 
six minutes as a reflection of their functional capacity. The 6MWT is a self-paced 
exercise test.  Subjects are allowed to stop and rest during the test and resume walking 
when they feel comfortable to do so.(6) The 6MWT is commonly used in clinical 
settings as a single measurement of physical functional status and as an outcome 
measurement of the response to treatment interventions in patients with moderate to 
severe heart or lung disease.(7, 8) The 6MWT has also shown a value in predicting 
morbidity and mortality.(9, 10) 
Aim 
The aim of this paper is to provide a review and critique of the current literature on the 
6MWT in relation to measuring and monitoring physical functional capacity, as well as 
discussing the potential of the 6MWT as a self-administered tool. 
Method 
A modified integrative review method was used to provide a critique of the 6MWT 
literature. The modified integrative review summarises and analyses both experimental 
and non-experimental studies to provide a more comprehensive understanding of the 
study phenomenon and to identify the needs to inform future research studies.(11) A 
literature search was conducted on studies reporting the 6MWT in people with CHD 
using the Medline, Cumulative Index of Nursing and Allied Health (CINAHL), the 
Science Direct databases and the World Wide Web using Google search engine. 
Reference lists of retrieved articles were hand searched for any additional references. 
The key words included were “chronic heart disease”; “chronic heart failure”; 
“walking”, “exercise-test”, “six-minute walk test”; “6MWT;” and “physical functional 
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status. Studies reporting the use of the 6MWT as an outcome measure, without 
methodological considerations, were excluded from the review. 
Findings of the integrative literature review 
The search strategy, yielded 386 publications from 1985-2008. Using the selection 
criteria of studies reporting administration, reliability and validity of the 6MWT, 34 met 
the inclusion criteria.  Key issues derived from the literature are discussed below. 
The Six Minute Walk Test 
The 6MWT test was first developed by Balke in the 1960s (12) to evaluate functional 
capacity. The 6MWT is a simple test that measures the distance walked during a defined 
period. The duration of the walk test was initially 12-minutes. Different versions of the 
walk test have been tested for their correlation to the gold standard of graded, symptom 
limited exercise tests, such as treadmill exercise tests.(1) Studies have demonstrated that 
a 3-minute walk test and the 6MWT performed as well as a 12-minute walk test.(13, 14) 
Their reproducibility are also similar.(13) However, when the duration of a walk test is 
under 4 minutes, the result is not sensitive enough for evaluating differences in distance 
walked.(15) The 6MWT is a sensible compromise and is currently the most commonly 
used walk test. 
The 6MWT was first used as a standard test in the clinical settings of chronic 
respiratory disease and respiratory failure.(8, 16) The test is easy to perform, interpret 
and particularly useful in conditions such as chronic heart failure (CHF), that are 
characterised by diminished functional capacity.(8) The first studies assessing the 
6MWT in patients with heart disease, were undertaken by Guyatt et al.(17) and Lipkin 
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et al.(18), reporting that the 6MWT can differentiate the most compromised heart 
failure patients from the less severe cases according to the New York Heart Association 
(NYHA) functional class classification.(9, 10) 
Peak oxygen uptake, functional capacity and the 6MWT 
 
Functional capacity is often expressed by peak VO2  during maximal exercise 
testing.(19) Peak VO2 is a strong indicator of the severity of CHF, (20) as well as an 
independent predictor of mortality. The endorsement of peak VO2 assessment in the 
cardiac transplantation guidelines has also confirmed its prognostic value.(20) Peak 
VO2, assessed during the 6MWT, has shown similar reproducibility and accuracy when 
compared to the shuttle walk test, an incremental form of exercise testing. (21). The 
peak VO2 is approximately 10-20% higher during the maximal exercise test compared 
to submaximal exercise testing.(6) In people with advanced conditions, maximal 
exercise testing may be contraindicated due to significant impairment in functional 
capacity. In this case, assessing the highest VO2
There is consensus that the 6MWT is a simple, safe exercise test.(4, 18, 22, 23) Strong 
correlations between the 6MWT distance and the peak VO
 from a submaximal exercise test is 
useful but can be less predictive of prognosis. 
 
2 (r=0.56 to r=0.88) have 
been reported.(23) Faggiano et al.,(23) demonstrated that in a quarter of the participants, 
their VO2 during the 6MWT, was higher than their anaerobic threshold, that is their 
peak VO2.(24) Another study performed by Riley et al., showed a similar result, that is 
the VO2 during the 6MWT is similar or higher than peak VO2.(23) Riley et al., did not 
measure VCO2, therefore the participant’s anaerobic threshold was unknown. These two 
studies suggested that in people whose physical functional capacity is severely impaired, 
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an exercise test of a submaximal nature could be a reflective of the results obtained 
from a maximal exercise test.  
Prognostic value of the 6MWT 
There is no consensus regarding the prognostic value of the 6MWT. As a consequence 
of a “ceiling effect”, that is where the test result is too high to detect further significant 
improvement, both clinically and statistically,(25).  The 6MWT has perhaps its greatest 
application in the CHF population, where functional capacity is impaired and periods of 
decompensation are common. Most studies examining the prognostic value of the 
6MWT have been done in people with CHF. The prognostic value of the 6MWT was 
first reported by Bitter et al.(26) in the Studies of Left Ventricular Dysfunction 
(SOLVD) study, enrolling 898 participants with CHF over a follow up period of 242 
days. In Bitter et al.’s study, the mortality rate was 10.23% in individuals who walked 
less than 350 metres, and 2.99% (p<0.01) in participants, walking more than 450 metres 
on a  6MWT. Subsequent studies have demonstrated that the 6MWT distance is 
prognostically useful in predicting mortality and hospitalisation.(26, 27) In one study 
examining the relationship between the 6MWT distance and outcome of a population of 
stable outpatients with CHF, 541 participants undertook the 6MWT at baseline. 
Following a median of 32 months follow up, a shorter 6MWT distance at baseline 
(<200 metres) was associated with significantly higher risk (59% higher, p<0.001) of 
all-cause mortality.(28) However, studies comparing the 6MWT with other tests, such as 
symptom limited cycle ergometry (22) and standard indices of cardiac function, show 
only a moderate correlation between the 6MWT distance and exercise capacity.(8, 22, 
29) These studies suggest that the 6MWT distance is not an independent prognostic 
indicator, but a complement or substitute for the peak oxygen uptake (peak VO2) or 
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NYHA-functional class.(22) Although, the 6MWT may not be a standard, independent 
prognostic indicator, compared with peak VO2, assessed
The 6MWT distance in CHD population and in the healthy adult 
The distance walked in the 6MWT has been used in people with heart disease to 
evaluate functional capacity. In a study with 315 participants, with moderate to severe 
heart failure, the 6MWT distance ranged from 134 metres to 686 metres.(28) Generally 
a distance of less than 300 metres is considered as the threshold for increased risk of 
mortality, with only one study suggested 200 metres.(30-33) The discrepancy of the 
threshold distance may be due to the difference in the 6MWT protocol used, such as the 
use of encouragement.  Stopping and resting during the test that are known to influence 
the walk test distance. 
In order to derive normative data and assist in interpreting test results, the 6MWT 
distance in the healthy population provides a useful reference point. Four published 
studies have provided normative data in healthy adults.(30) Enright and Sherrill(30) 
have developed equations to calculate the distance walked by healthy adult during 
6MWT. These are: 
 during maximal exercise testing; it 
certainly provides valid and important information regarding individual’s functional 
capacity.  
• 6MWT distance = (7.57 X heightcm) – (5.02 X age)- (1.76 X weightkg
• 6MWT distance = (2.11 X height
) – 309m 
for men 
cm) - (2.29 X weightkg
These two equations are based on 6MWT performance of 117 healthy man and 173 
healthy women aged 40 to 80 years. In this study, the mean 6MWT distance was 576 
) -(5.78 X age) + 667m 
for women  
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metres for men and 494 metres for women.(31) Among the other three studies, the study 
by Gibbons et al.,(32) which recruited a sample of young participants with a mean age 
of 45.1 years reported the longest mean 6MWT distance of 698 metres. Steffen et 
al.,(33) studied a sample of elderly people with a mean age of 74.1 years. In this study 
the mean 6MWT distance was 505 metres for men and 467 metres for women. Trooster 
et al.,(8) reported that  a mean 6MWT distance of 613 metres where the average age of 
participants was 65years. These four studies not only provide a reference point for 
interpreting the 6MWT distance. These data also show the relationship between 
anthropometric variables, gender, age and the 6MWT distance.(31, 34) The 6MWT 
distance is inversely correlated with age,(31) which is greater in men than women by an 
average of nearly 76 metres.(14, 29, 35)  
Practical application of the 6MWT: methodological considerations 
From the existing literature, the 6MWT protocol varies from study to study. Key 
variances in protocol relate to using encouragement and the use of practice tests before 
formal assessment of the 6MWT distance. Besides the anthropometric variables 
mentioned in the previous section, the 6MWT distance can certainly be influenced by 
the variations in 6MWT protocols. Some of the methodological issues to be considered 
in interpreting results are discussed below.  
The learning effect 
The distance walked during the 6MWT tends to increase (+19 metres when the two tests 
are done 30 minutes apart) and over the first five walks (p<0.001).  The largest 
improvements in distance walked is seen over the first 3 walks.(36) There is no 
significant difference between measurement taken 30 minutes and 24 hours apart 
(p=0.99).(29).  These observations relate to the learning effect. It is calculated that the 
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minimum variation in the 6MWT distance that can be considered as an expression of a 
real variation of functional capacity is approximately 10% of the average of two 
consecutive tests.(29, 37) Therefore, it is commonly agreed that one or two practice 
6MWT can be useful before using it to measure physical functional capacity.(4, 23, 30, 
38)  
The use of encouragement 
Several studies have used standard verbal encouragement during the test, (9, 14, 29, 34) 
while others have not.(9, 14, 39) The use of encouragement during a 6MWT has an 
impact on the test result.(6) However, the reproducibility of the 6MWT result, with or 
without encouragement, are similar.(6) Although the American Thoracic Society (ATS) 
6MWT guideline recommends using standard encouragement during the test,(40) the 
decision regarding the use of encouragement during the test should depend on the nature 
and purpose of the study. 
Reliability of the 6MWT 
Reliability refers to the ability to measure the same result on repeated tests. (40) The 
intraclass correlation coefficient (ICC) is a measure of reliability. An ICC of greater 
than 0.75 is considered adequate and 0.90 is considered excellent.(40) A study 
undertaken by Dermers and colleagues, (40) in the Randomized Evaluation of Strategies 
for Left Ventricular Dysfunction (RESOLVD) pilot study, assessed the reliability, 
validity and responsiveness of the 6MWT. The participants in the RESOLVD pilot study 
were a group of stable CHF patients with NYHA II-IV symptoms. In this study, the 
6MWT was repeated twice at each of the three measurement times over a period of 34 
weeks, the test-retest reliability was high with an ICC of 0.85.(4, 34, 41) Other studies 
have reported the ICC of repeated 6MWTs ranging from 0.75 to 0.97. (4) Only one 
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study reported a significant difference between the distance of two consecutive 6MWTs, 
leaving these authors to conclude that the 6MWT distance to be not reproducible in their 
study.(40) In this particular study, the period between two tests was unknown, it is also 
not known if learning effect was another contributing factor to the result of this study. 
Despite the variations among the 6MWT protocol in each study, such as whether there 
was  a practice test, or encouragement was used existing data suggests that the 6MWT is 
a reliable measurement of functional capacity.  
Validity of the 6MWT 
Validity describes the relationship between an attribute under evaluation and other 
attributes.(40) Sousa and colleagues studied the utility of the 6MWT in Chagas disease. 
The results from their study suggested that there is a negative correlation between  the 
6MWT distance and the increased circulating levels of monocyte chemosttractant 
protein (MCP-1, r=-0.358, p=0.04);(42) a negative correlation between the 6MWT 
distance and natriuretic peptide type B (BNP, r=-0.349, p=0.04); and a positive 
correlation between left ventricular ejection fraction and the 6MWT distance (r=0.451, 
p=0.004) (42).The 6MWT has also been compared with other assessment tools such as 
the NYHA-functional class and measures of health related quality of life (HRQoL), 
including the disease specific Minnesota Living with Heart Failure Questionnaire 
(MLHFQ)(34) and the physical functioning domain of the generic HRQoL measure, the 
Short Form-36 (SF-36).(40) The 6MWT has also been shown to have a weak and 
inverse correlation (r=-0.39) with the MLHFQ, and likewise, an inverse correlation (r=-
0.45) between the 6MWT distance and the NYHA scale (p=0.058).(34) The correlation 
between the 6MWT distance and the SF-36 physical functional section was 0.623 
(p<0.001).(40) Questionnaires examining HRQoL are subjective, multidimensional self-
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report tools, consisting of other domains other than physical functioning. The physical 
function domain of the SF-36 is better in reflecting physical activity; therefore, a weak 
correlation between 6MWT and QOL, and stronger correlation between 6MWT and SF-
36 physical function section are expected. These data discussed above, suggests the 
6MWT is a valid measurement tool for physical functional capacity. However, it focuses 
explicitly on physical functioning and is not representative of other aspects of HRQoL 
Responsiveness of the 6MWT 
The responsiveness or sensitivity to change assesses the ability of a test to measure 
change over time or the ability to measure the effectiveness of treatment.(38) In one 
study, the 6MWT was found to be more sensitive in evaluating the effectiveness of an 
exercise intervention compared to Duke Activity Scale Index (DASI) (r=-0.42).(40) In 
the RESOLVD pilot study the standardized means were statistically significant for 
participants who were receiving candesartan and enalapril.(43) A similar result was 
found in another double blind, randomized, placebo controlled trail, where the mean 
6MWT distance increased by 37.1 metres (p<0.001) over a ten weeks follow up in the 
intervention group receiving perindopril.(1) However, the utility of 6MWT in assessing 
the effectiveness of pharmacological interventions is not convincing. The systematic 
review by Olsson,(1) summarized all clinical trails done on the 6MWT in assessing the 
effectiveness of treatments up till 2004. There were 46 placebo-controlled trials, 39 
pharmacological interventions and 7 non-pharmacological interventions. The changes in 
the 6MWT distance before and after intervention is significant in four out of the seven 
non-pharmacological interventions, and only significant in nine out of the 39 
pharmacological interventions. The majority of the pharmacological trials, showing no 
significant changes in the 6MWT distance, were done in assessing the effectiveness of 
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angiotensin-converting enzyme inhibitors and beta-blockers.(44, 45)  These data 
underscore the importance of choosing outcome variables that are most responsive to 
the study question being addressed.  
The 6MWT- can it be a self-administered process and outcome 
measurement tool? 
The data discussed above demonstrates the validity and reliability of the 6MWT and 
factors influencing the test result. Self-monitoring of functional capacity in CHD has 
been limited by the use of an empirical tool. High levels of subjectivity affect the 
description of fatigue and shortness of breath is common in many heart conditions. In 
diabetes, the use of glucose monitoring and the use of spirometry in people with 
respiratory conditions have been shown to increase the capacity of individuals to 
understand and manage their condition.(1) A self-monitoring tool for functional capacity 
in CHD, has the capacity to monitor physical health status and symptoms over time. 
As discussed above, the cardiopulmonary exercise, bicycle and treadmill exercise tests 
and the shuttle walk are commonly used exercise tests.(20, 46) They are either high-
intensity or incremental. Peak oxygen uptake can be monitored during these maximal 
exercise tests, by using a tight mask for gas analysis. Because of the risk of developing 
arrhythmias, and acute cardiac events, maximal exercise tests are often contraindicated 
in populations with severe heart disease.(20, 47) In addition, appropriately trained 
health professionals are required to administer the test.  
These factors limit the usefulness of the maximal exercise test in monitoring functional 
status over time. In spite of the robust data derived from maximal exercise testing, many 
patients are reluctant to exercise with the equipment required in the test, particularly 
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those whose activities of daily living are symptom limited.(5) The use of a submaximal 
exercise test could meet the needs of people with functional limitations and the needs of 
older adults, whose functional capacity are limited. However, the submaximal exercise 
tests and their applications have been less well developed and is an important area for 
future research.(38) We postulate that the 6MWT could potentially be adapted as a self-
administered test for the following reasons, 
The 6MWT is a widely acceptable self-paced submaximal exercise test in conditions, 
such as moderate to severe CHF where maximal exercise testing is contraindicated or 
where access to equipment is limited. Further, the 6MWT is likely to be less 
intimidating in older people, particularly women.(38) In people with severe CHF, the 
6MWT provides prognostic information on morbidity and mortality, reflecting physical 
function aspect of HRQoL in measuring impairment. As discussed above, the reliability, 
validity and responsiveness of the 6MWT have been extensively tested in clinical 
settings. Gary et al.(48, 49) conducted a study examining the use of the 6MWT to 
evaluate the effectiveness of a 12-week home walk exercise program, in a group of 
women with diastolic heart failure. Participants were asked to keep a record of the times 
they walked weekly, as well as their heart rate before, during and after each training 
session. The rate of adherence to the program protocol in this study was 85% in the 
participant group. There were also other home-based exercise programs in the literature 
showing positive effects on patients physical functioning and overall wellbeing. 
However the effects of these exercise programs are affected by its low program 
adherence.(38)  
 
Compared to the Home Walk program in the study by Gary et al.,(38) the 6MWT 
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protocol is simpler to follow. Potentially, the 6MWT has the advantage and the potential 
to be a self-administered measurement tool. This approach will allow a two-pronged 
approach. Firstly, as a therapeutic intervention to improve functional activity and 
secondly provide utility as a therapeutic index. (50) Strategies that promote the 
individual in engaging and monitoring their own clinical condition can potentially 
improve health outcomes.  
Significance and Implications 
An important focus of CHD management is monitoring physical functional capacity and 
promoting self-management. Frequently, people with CHD often need to make 
modifications to their lifestyle to cope and adjust to their chronic condition.(51) 
Effective self-management has been shown to give individuals a sense of control over 
their life in the context of their chronic condition, therefore promoting healthy lifestyle 
and emotional stability. (52, 53) 
 
The 6MWT is a simple, inexpensive test, not dependent on technological requirements. 
Based upon the observations reported above, the 6MWT appears promising to 
investigate as a self-administered tool. (50). Physical assessment is a critical 
consideration in many chronic conditions. Therefore, a self-directed approach, focussing 
on self-management and physical activity, will likely improve people’s capacity to 
better monitor their conditions and provide their clinicians with empirical data to inform 
their management decisions. For example, if such an intervention is demonstrated to be 
successful, this could easily be incorporated in cardiac rehabilitation and other chronic 
disease management programs. Through implementing a self-administered 6MWT into 
a nurse-led disease management program, there is also the potential to improve clinical 
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outcomes through early recognition of changes in activity that may alert both the patient 
and clinician to exacerbations. Within the context of the growing burden of CHD, this 
potential approach is timely as it extrapolates an inexpensive, valid and reliable 
assessment tool, with strong predictive power, to self-management by the individual in a 
community based setting. 
Conclusion 
Maximal exercise testing has been the gold standard for assessing functional capacity, 
though it has its limitations. The 6MWT can provide valid and reliable information of 
individual’s physical functional capacity. The 6MWT is potentially more representative 
of the individual’s daily activity, compared with maximal exercise testing methods. As a 
self-administered assessment tool to promote physical activity and self-management 
strategies, the 6MWT may be useful in improving the community-based management of 
CHD.  Therefore, further studies evaluating the acceptability and utility of the 6MWT 
and its protocol as a self-administered tool are required. 
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